Acrotech Biopharma to Acquire Hematology/Oncology Portfolio from Spectrum Pharmaceuticals

January 23, 2019

San Diego – Paul Hastings LLP, a leading global law firm, announced today that the firm represented Spectrum Pharmaceuticals, Inc. (NASD: SPPI), a leading biotechnology company focused on acquiring, developing and commercializing drug products, in its pending sale of seven FDA-approved hematology/oncology products to Acrotech Biopharma LLC, a subsidiary of Aurobindo Pharma USA, Inc., for up to $300 million.

Corporate Partner Carl R. Sanchez in San Diego led the Paul Hastings team, which also included associates Spencer Young, Tyler Dodge and Philip Dodd.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.